Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.

NCT05840562 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT05840562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05840562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Phase 3
Overall status
Recruiting
Start date
October 20, 2023
Completion date
March 31, 2028
Enrollment
274 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy